KRAS and non-small cell lung carcinoma: The CheckMate 057 trial provided early insights into this association, demonstrating a marked improvement in OS with nivolumab compared to docetaxel in pretreated advanced NSCLC patients with KRAS mutations, yielding a HR of 0.52 [109] (Table 1).